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Alterations in T regulatory cells (Treg cells) play 
a critical role in autoimmune disorders, including 
inflammatory  bowel  disease  (IBD;  Zenewicz   
et al., 2009; Wing and Sakaguchi, 2010). IBD is 
a chronic inflammatory disorder that includes 
Crohn’s disease and ulcerative colitis, which are 
both characterized by gut infiltration of highly 
reactive CD4+ T cells (Mottet et al., 2003; Izcue 
et  al.,  2006).  Mutations  in  the  Foxp3  gene, 
which encodes a critical transcription factor for 
Treg cell development and function, lead to lym­
phoproliferative disorders associated with fatal in­
flammation, both in humans and mice (Bennett 
et al., 2001; Brunkow et al., 2001; Fontenot   
et al., 2003, 2005; Wu et al., 2006). It has been 
proposed that other transcription factors act in 
concert with, downstream, or even upstream of 
Foxp3 in controlling Treg cell development and 
function  (Wu  et  al.,  2006;  Chaudhry  et  al., 
2009;  Kitoh  et  al.,  2009;  Koch  et  al.,  2009;   
Pan et al., 2009; Zheng et al., 2009). However, 
unlike  deletion  of  Foxp3,  lack  of  such  tran­
scription factors has not led to systemic lym­
phoproliferative diseases, but rather to more 
specific  pathologies.  For  instance,  removal  of 
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Dysregulated CD4+ T cell responses and alterations in T regulatory cells (Treg cells) play a 
critical role in autoimmune diseases, including inflammatory bowel disease (IBD). The 
current study demonstrates that removal of Bcl11b at the double-positive stage of T cell 
development or only in Treg cells causes IBD because of proinflammatory cytokine-producing 
CD4+ T cells infiltrating the colon. Provision of WT Treg cells prevented IBD, demonstrating 
that alterations in Treg cells are responsible for the disease. Furthermore, Bcl11b-deficient 
Treg cells had reduced suppressor activity with altered gene expression profiles, including 
reduced expression of the genes encoding Foxp3 and IL-10, and up-regulation of genes 
encoding proinflammatory cytokines. Additionally, the absence of Bcl11b altered the 
induction of Foxp3 expression and reduced the generation of induced Treg cells (iTreg cells) 
after Tgf- treatment of conventional CD4+ T cells. Bcl11b bound to Foxp3 and IL-10 
promoters, as well as to critical conserved noncoding sequences within the Foxp3 and IL-10 
loci, and mutating the Bcl11b binding site in the Foxp3 promoter reduced expression of a 
luciferase reporter gene. These experiments demonstrate that Bcl11b is indispensable for 
Treg suppressor function and for maintenance of optimal Foxp3 and IL-10 gene expression, 
as well as for the induction of Foxp3 expression in conventional CD4+ T cells in response to 
Tgf- and generation of iTreg cells.
© 2011 VanValkenburgh et al.  This article is distributed under the terms of an 
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six 
months after the publication date (see http://www.rupress.org/terms). After six 
months it is available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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also in mice solely lacking Bcl11b in Treg cells. The IBD was 
caused by alterations in Treg cells, as provision of WT Treg 
cells prevented the disease. Bcl11b­deficient Treg cells pre­
sented reduced suppressor function, with reduced levels of 
Foxp3  and  IL­10,  and  increased  CD4+ T  cell  proinflam­
matory cytokines Tnf, IFN­, and IL­17, as well as other altera­
tions in Foxp3­dependent and ­independent Treg cell genetic 
program. Mechanistic experiments demonstrate that Bcl11b 
bound to conserved noncoding regions in the Foxp3 and IL-10 
genes, therefore participating in regulation of expression of 
these genes. Additionally, in the absence of Bcl11b, induction 
of Foxp3 expression in peripheral conventional CD4+ T cells, 
and consequently the generation of Treg cells, was affected. 
These results demonstrate critical roles of Bcl11b in Treg cells.
RESULTS
Bcl11bF/F/CD4-Cre mice develop wasting disease  
associated with IBD
We previously observed that mice lacking Bcl11b starting 
with the DP thymocytes displayed splenomegaly and enlarged 
mLNs,  starting  at  5–7  wk  of  age. Additionally,  the  CD4+  
T lymphocytes presented an effector phenotype (Albu et al., 
2007). Further investigation of these mice demonstrated that 
they presented significantly lower weights starting with 10–12 
wk of age (Fig. 1 A). Gross examination of the colons showed 
enlargement and thickening (Fig. 1 B), and hematoxylin and 
Stat3 from Treg cells resulted in the inability of these cells to 
suppress Th17 immune responses, which consequently caused 
intestinal  inflammation  with  massive  infiltration  of  CD4+  
T cells (Chaudhry et al., 2009), whereas IRF4 deletion from 
Treg cells caused a Th2­predominant pathology. In addition, 
T­bet was found necessary for Treg cell function during Th1 re­
sponse  (Koch  et  al.,  2009),  whereas  Eos  was  required  for 
silencing of effector genes in Treg cells (Pan et al., 2009). Foxo1 
and Foxo3 were also required for blocking the acquisition of 
effector T cell phenotype by Treg cells (Ouyang et al., 2010).
Bcl11b  is  a  C2H2  zinc  finger  transcriptional  regulator 
(Avram et al., 2000, 2002), previously demonstrated to act 
both  as  a  transcriptional  repressor  and  activator  (Cismasiu   
et al., 2005, 2006, 2008, 2009). It is required for  and positive 
selection and survival of DN3 and double­positive (DP) thy­
mocytes (Wakabayashi et al., 2003; Albu et al., 2007), in addi­
tion to controlling the commitment to T cell lineage of early 
thymic  precursors  (Ikawa  et  al.,  2010;  Li  et  al.,  2010a,b)   
and antigen­specific clonal expansion and cytolytic function of 
CD8+ T  lymphocytes  (Zhang  et  al.,  2010).  Mice  lacking 
Bcl11b starting with DP thymocytes displayed splenomegaly 
and  enlarged  mesenteric  LNs  (mLNs),  and  the  CD4+  
T lymphocytes presented an effector phenotype (Albu et al., 
2007). In this study, we further show that these mice develop 
IBD with massive colon infiltrations of proinflammatory   
cytokine–producing CD4+ T cells. Additionally, this occurred 
Figure 1.  Bcl11bF/F/CD4-Cre mice develop wasting disease, caused by IBD, associated with massive infiltrations of CD4+ T cells in the 
colon. (A) Weights of Bcl11bF/F/CD4-Cre and WT mice were recorded starting at 4 wk of age (n = 6 mice per group). Asterisks indicate statistical sig-
nificance determined by unpaired two-tailed Student’s t test (*, P < 0.05). (B) Representative colon gross anatomy of Bcl11bF/F/CD4-Cre and WT mice 
12–16 wk of age. (C) Representative H&E staining of colon sections of a similar area along the length of the colon from Bcl11bF/F/CD4-Cre and age- 
and sex-matched WT mice at 15–16 wk of age. The bottom panel shows a higher magnification image of the marked areas in the KO section. (D) Alcian 
blue counterstained with Nuclear Fast red of colon sections from Bcl11bF/F/CD4-Cre and WT mice, indicating in blue mucus-producing goblet cells. 
Bars, 100 µm. (B–D) Data are representative of at least 10 pairs of mice. (E) Histological scores of colitis at 15–16 wk of age, using the criteria  
described in Table S1. P (evaluated by unpaired two-tailed Student’s t test) = 4.52 × 108. The error bar indicates SD. (F) Absolute numbers of total 
cells in the colon LP and epithelium (IEL) of Bcl11bF/F/CD4-Cre versus WT mice. (G) Absolute numbers of CD4+ T cells present in the colon LP and epi-
thelial compartment (IEL). (F and G) Asterisks indicate statistical significance as determined by unpaired two-tailed Student’s t test (*, P < 0.05).  
Horizontal bars indicate the mean. (H and I) Frequencies of CD4+ and CD8+ T cells among the colon LP lymphocytes (H) and IELs (I) evaluated by flow 
cytometry. (E–I) Data are derived from four to five mice per group.JEM Vol. 208, No. 10 
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T lymphocytes of Bcl11bF/F/CD4­Cre mice show consider­
able up­regulation of CCR9 and integrin 47 in the mLNs 
and spleen (Fig. 2 A), in addition to CD44 (Fig. S1 B). Up­
regulation of 47 integrin and CD44 but not CCR9 was 
already observed in the DP and single­positive thymocytes, 
where the removal of Bcl11b was initiated (Fig. 2 B and 
not depicted). 47 integrins and CD44 messenger RNA 
(mRNA) levels were also up­regulated in DP thymocytes 
(Fig. 2 C). These results collectively demonstrate that Bcl11b­
deficient CD4+ T cells show an abnormal and premature ac­
tivation of gut­homing markers, which perhaps favors their 
accumulation in the colon.
Bcl11bF/F/CD4-Cre mice colons contain large numbers  
of infiltrating Th1 and Th17 cytokine–producing CD4+  
T cells, neutrophils, dendritic cells, and macrophages
The proinflammatory Th1 and Th17 cytokines have a major 
impact  on  IBD  development  and  progression  (Zenewicz   
et al., 2009). We therefore investigated whether the accu­
mulated CD4+ T cells in the colon produce proinflammatory 
cytokines. Our results demonstrated that there was a marked 
increase  in  the Th1  and Th17  cytokine–producing  CD4+  
T cells in the colon of diseased Bcl11bF/F/CD4­Cre mice 
(Fig. 3, A and B). Additionally, the increased IEL CD4+CD8+ 
cell population (Fig. 1 I) showed elevated levels of Tnf (Fig. 3 C). 
The H&E staining of the large intestine suggested that some 
eosin (H&E) and Alcian blue staining indicated disruption of 
the crypt architecture, epithelial damage, massive infiltration 
of leukocytes, and loss of goblet cells (Fig. 1, C–E). Infiltrates 
in the liver were also observed (not depicted), which are all 
characteristics of IBD (Ito et al., 2006).
Bcl11bF/F/CD4-Cre mice present large numbers of CD4+  
T cells infiltrating the colon lamina propria (LP)  
and epithelium
The percentage and absolute numbers of CD4+ and CD8+  
T cells were reduced in the peripheral lymphoid organs of 
Bcl11bF/F/CD4­Cre mice, including mLNs and Peyer’s patches 
(Fig. S1 A; Albu et al., 2007), which is believed to be a conse­
quence of the developmental block at the DP stage of T cell 
development (Albu et al., 2007). The CD4+ T cells in the   
peripheral lymphoid organs presented an effector/memory 
phenotype (Fig. S1 B; Albu et al., 2007). Conversely, the per­
centage and absolute numbers of CD4+ T cells were increased 
in the colon LP and intraepithelial lymphocyte (IEL) com­
partment (Fig. 1, G–I). Additionally, there was an increase in a 
CD4+CD8+ cell population in the IEL compartment (Fig. 1 I), 
which presented high levels of Tcr­. This population pre­
sented a slightly higher frequency of CD8ab versus CD8aa, 
compared with WT (Fig. S2, A and B). Overall, the total num­
ber of lymphocytes was increased both in the colon LP and 
IEL compartment (Fig. 1 F), in agreement with the massive 
infiltrates observed by histological analysis. Of note, the per­
centages and absolute numbers of CD8+ T cells were variable 
(Fig. 1, H and I; and Fig. S2 C; see Fig. 5 F). Similarly to what 
was reported for immature Bcl11b­deficient  T cells or Bcl11b­
deficient CD8+ T cells differentiated in vitro with the ER­
Cre system (Ikawa et al., 2010; Li et al., 2010a,b), a large 
population of Bcl11b­deficient CD8+ T cells of Bcl11bF/F/
CD4­Cre mice up­regulated Nk1.1 (Fig. S2 D). To deter­
mine whether the CD8+ T cells contributed to IBD, we gen­
erated Bcl11bF/F/CD4­Cre/b2m/ mice. b2m/ mice are 
almost devoid of CD8+ T cells because of defective positive 
selection of these cells in the thymus (Koller et al., 1990).   
Our results show that even in the absence of CD8+ T cells, 
Bcl11bF/F/CD4­Cre mice continued to present wasting dis­
ease (Fig. S2 E), suggesting that it is unlikely that the CD8+  
T cells, even though they up­regulated NK markers, have a 
critical contribution to the disease phenotype. In conclusion, 
these results collectively demonstrate that although the num­
bers of CD4+ T cells in the peripheral lymphoid organs of 
Bcl11bF/F/CD4­Cre mice were reduced, there was a pro­
found increase of CD4+ T cells in the colon, likely to be asso­
ciated with the IBD observed in these mice. In addition, our 
results suggest that the CD8+ T cells are unlikely to have a 
critical contribution to the disease phenotype.
Abnormal up-regulation of the gut-homing markers  
in Bcl11b-deficient T cells
To further investigate why the CD4+ T cells of Bcl11bF/F/
CD4­Cre mice accumulated in the colon, we evaluated sev­
eral gut­homing markers and found that peripheral CD4+  
Figure 2.  Bcl11bF/F/CD4-Cre mice show abnormal up-regulation of 
the gut-homing markers in T cells. (A) Frequencies of CD4+ T cells ex-
pressing the gut-homing markers 47 integrin and CCR9 in the mLNs 
and spleen of Bcl11bF/F/CD4-Cre and WT mice. (B) Frequencies of 47 
integrin and CD44-expressing CD4 single-positive and DP thymocytes in 
Bcl11bF/F/CD4-Cre and WT mice. (A and B) Data are representative of at 
least three pairs of mice. (C) Fold change in mRNA levels for 47 inte-
grins and CD44 in DP thymocytes from Bcl11bF/F/CD4-Cre mice. Data are 
representative of two independent microarrays.2072 Bcl11b controls regulatory T cells | VanValkenburgh et al.
Treg cells in the peripheral lymphoid organs were reduced 
compared with WT (see Fig. 7 A and not depicted). However, 
their absolute numbers were significantly increased in the 
colon (Fig. 4, A and B), in agreement with the up­regulation 
of the integrin 47 and CCR9 in these cells as well (Fig. S4 A). 
Even though Treg cells accumulated in the colon, the conven­
tional CD4+ T cells produced elevated levels of proinflam­
matory cytokines, raising the possibility that the Treg cells 
may not be able to suppress the conventional effector CD4+  
T cells. To address this question, we conducted in vitro sup­
pression  assays,  and  the  results  demonstrated  that  Bcl11b­ 
deficient Treg cells were unable to control the proliferation of 
effector CD4+ T cells with the same efficiency as WT Treg cells 
(Fig. 4 C). Furthermore, this was not caused by a significant 
defect in their maintenance in vitro (Fig. S4 B). Not only 
the Treg  cells  of  Bcl11bF/F/CD4­Cre  mice  showed  altered 
suppressor function, but Bcl11b­deficient Treg cells derived 
from mice in which Bcl11b was solely removed in Treg cells 
(Bcl11bF/F/Foxp3­Cre mice) also showed a similar phenotype 
(Fig. 4 D). These results collectively demonstrate that Bcl11b­
deficient Treg cells are present in the colon; however, their sup­
pressor function is altered.
Provision of the WT Treg cells prevented the IBD  
in Bcl11bF/F/CD4-Cre mice
To further determine whether the IBD observed in Bcl11bF/F/
CD4­Cre mice is indeed a consequence of altered Treg cell func­
tion, we transferred WT Treg cells in 4–5­wk­old Bcl11bF/F/
CD4­Cre mice, before these mice showed 
any disease signs. Provision of WT Treg 
cells  prevented  the  wasting  disease  in 
Bcl11bF/F/CD4­Cre mice (Fig. 5 A), and 
of the infiltrating cells could be polymorphonuclear leuko­
cytes. The flow cytometry data show that there was also a sig­
nificant increase in the neutrophil, macrophage, and dendritic 
cell populations in the colon, both in the LP and IEL com­
partment (Fig. 3, D and E). The presence of neutrophils, macro­
phages, and dendritic cells in the IEL compartment is unusual 
even for diseased mice. We thus conducted immunohisto­
chemistry to determine whether indeed such cells are present 
in the epithelium compartment of diseased mice or perhaps 
their presence in the IEL preparation was a consequence of 
contamination with cells from LP. Although it was clear that 
in the WT the presence of neutrophils, macrophages, and 
dendritic cells was confined to the LP, in the Bcl11bF/F/CD4­
Cre mice, some of the cells seem to reach the epithelium layer 
area (Fig. S3). However, the colon structure in these mice be­
came disorganized, therefore making it difficult to conclude 
on the precise location of these cells in the colon epithelium 
layer. These results clearly demonstrate that there was an ac­
cumulation of the CD4+ T cells producing proinflammatory 
cytokines in the colon, as well as of neutrophils, dendritic 
cells, and macrophages, which together with the Th1 and 
Th17 CD4+ T cells are likely to participate in the disease.
Bcl11b-deficient Treg cells have reduced in vitro  
suppressor function
To further investigate why the cells in the colon produced 
uncontrolled cytokines, we evaluated the Treg cells of Bcl11bF/F/ 
CD4­Cre mice. The percentages and absolute numbers of   
Figure 3.  Colons of Bcl11bF/F/CD4-Cre mice 
accumulate proinflammatory cytokine– 
producing CD4+ T cells, neutrophils, dendritic 
cells, and macrophages. (A and B) Intracellular 
cytokine production by CD4+ T cells isolated from 
the colon LP (A) and epithelium (IEL; B) of Bcl11bF/F/ 
CD4-Cre and WT mice. (C) Intracellular cytokine 
production by colon IEL CD4+ CD8+ T cells.  
(A–C) Cells were isolated and activated as de-
scribed in Materials and methods, followed by 
staining for surface CD4 and CD8 and intracellu-
larly for the indicated cytokines, and analyzed by 
flow cytometry. Frequencies of cytokine-producing 
cells are indicated within the gated CD4+ T or CD4+ 
CD8+ T cell population. (D and E) Frequencies of 
neutrophils, dendritic cells, and macrophages in 
the colon LP (D) and epithelium compartment (IEL; E) 
are shown. Cells were isolated as described in  
Materials and methods, stained for CD4, CD8, Gr1, 
CD11c, and F4/80, and analyzed by flow cytometry. 
The numbers in the dot plots and histograms indi-
cate the percentage of Gr1hi, CD11c+, and F4/80+ 
populations, respectively, within the gated 
CD4CD8 population. The data are representative 
of four to five pairs of mice.JEM Vol. 208, No. 10 
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most of the Bcl11bF/F/CD4­Cre mice did not survive over 
16–18 wk of age (Fig. 1 A and not depicted). In addition,   
5­mo­old and older Bcl11bF/F/Foxp3­Cre mice started to 
have enlarged spleens and colon inflammation with cellular 
infiltrations and reduction in goblet cells (Fig. 6, B–D; and 
Fig. S5 A). We thus investigated the removal of Bcl11b in 5–6­
wk­old Bcl11bF/F/Foxp3­Cre mice versus 20­wk­old mice 
and  found  that  although  removal  of  Bcl11b  occurred  in   
Treg cells from 20­wk­old mice, there was no removal of the 
gene in the Treg cells from young mice, whereas Bcl11b was 
removed in 5–6­wk­old CD4­Cre mice (Fig. S5 B). Of note, 
the levels of Bcl11b in WT and knockout cells should be 
evaluated only in relation to each other in each panel. We do 
not know at the moment whether there are variations in 
Bcl11b levels in WT cells related to age or whether these are 
experimental variations. Thus, these results suggest that re­
moval of Bcl11b in the Bcl11bF/F/Foxp3­Cre mice is delayed 
compared with the CD4­Cre model, which is likely to be re­
sponsible for the late onset of disease. Indeed the Foxp3­Cre 
deleter used in this study is a low Cre­expressing line. Despite 
this fact, similarly to the 15­wk­old CD4­Cre mice, 5–6­mo­old 
Bcl11bF/F/Foxp3­Cre mice had CD4+ T cells infiltrating in 
larger numbers in the colon compared with age­ and sex­
matched controls (Fig. 6 G), although in the periphery their 
numbers were comparable with WT mice (Fig. 6 E). This oc­
curred despite the fact that the conventional CD4+ T cells of 
the colon did not present enlargement or thickening (Fig. 5 B). 
H&E and Alcian blue staining showed normal structure of the 
colon, with normal crypts containing abundant goblet cells, 
and only minor infiltrates (Fig. 5, C–E). Flow cytometry analy­
sis demonstrated a marked reduction in the number of CD4+ 
T cells infiltrating the colon (Fig. 5 F), as well as in the CD4+ 
T cells producing IFN­ and Tnf, but surprisingly not IL­17 
(Fig. 5 G). Prevention of disease as a result of WT Treg cell 
provision was not caused by a defective maintenance of 
Bcl11b­deficient Treg cells in the presence of WT Treg cells 
(Fig. 5 H). These results demonstrate that provision of WT Treg 
cells prevented IBD, strongly suggesting that the alterations in 
Bcl11b­deficient Treg cells are very likely the cause of IBD.
Removal of Bcl11b solely in Treg cells causes IBD
We showed above that the absence of Bcl11b starting with 
DP thymocytes caused functional alterations in Treg cells, in­
cluding reduced suppressor function (Fig. 4 C). Importantly, 
Bcl11b­deficient Treg cells from Bcl11bF/F/Foxp3­Cre mice 
also showed altered suppressor function (Fig. 4 D). We further 
evaluated Bcl11bF/F/Foxp3­Cre mice and found that they de­
veloped IBD; however, there was a delay in the onset, and the 
severity of the disease was reduced compared with the CD4­
Cre model. Specifically, Bcl11bF/F/Foxp3­Cre mice failed to 
gain weight only at 20 wk of age (Fig. 6 A), whereas this 
occurred in Bcl11bF/F/CD4­Cre mice at 10–12 wk, and 
Figure 4.  Treg cells of Bcl11bF/F/CD4-Cre 
and Bcl11bF/F/Foxp3-Cre mice show  
altered suppressor activity in vitro. (A and B) 
Evaluation of absolute numbers of Treg cells in 
the colon of Bcl11bF/F/CD4-Cre/Foxp3-GFP 
mice. Cells were isolated from the colon LP 
and epithelial compartment (IEL) stained for 
CD4 and analyzed by flow cytometry, and the 
percentage of Foxp3-GFP+ cells and their 
absolute numbers were evaluated. Four to five 
mice were used for each group. Asterisks indi-
cate statistical significance determined by 
unpaired two-tailed Student’s t test (*, P = 
0.04 in A; *, P = 0.02 in B). Horizontal bars 
indicate the mean. (C and D) Sorted 
CD4+CD45RbhiFoxp3-GFP CFSE-labeled WT  
T cells were activated and co-cultured with 
sorted Foxp3-GFP+ Treg cells from Bcl11bF/F/
CD4-Cre/Foxp3-GFP+ or Foxp3-GFP+ mice (C) 
or from Bcl11bF/F/Foxp3-Cre or Foxp3-Cre 
mice (D) at the indicated ratios of conven-
tional T cells to WT or KO Treg cells (conven-
tional/Treg cells). After 72 h, cells were stained 
with anti–CD4-APC-Cy7 and anti–Foxp3-APC 
antibodies and analyzed by flow cytometry. 
The number of cell divisions was evaluated in 
the CD4+/Foxp3 population based on gradual 
loss of CFSE fluorescence. The maintenance of 
Bcl11b-deficient and WT Treg cells during the 
suppression assay is shown in Fig. S4 B. The 
results are representative of three indepen-
dent experiments, each with one pair of mice.2074 Bcl11b controls regulatory T cells | VanValkenburgh et al.
Bcl11b is required for optimal expression of Foxp3  
and binds to regulatory regions of the Foxp3 gene
We further investigated the mechanisms responsible for re­
duced suppressor function of Bcl11b­deficient Treg cells. The 
first observation was that the level of Foxp3 was reduced in 
Bcl11b­deficient Treg cells compared with controls both in the 
Bcl11bF/F/CD4­Cre  mice  and  Bcl11bF/F/Foxp3­Cre  mice 
(Fig. 7, A and C). The reduction was not only in the Foxp3 
protein level, but also in the Foxp3 mRNA (Fig. 7, B and D; 
and Fig. S6, A and B). Bcl11b­deficient T cells have been   
previously shown to have altered TCR signaling and re­
duced expression of TCR complex components (Albu et al., 
2007; Li et al., 2010a,b; Zhang et al., 2010). Therefore, Bcl11b 
Bcl11bF/F/Foxp3­Cre mice only minimally up­regulated CCR9 
and 47 integrin (Fig. S5 C). The splenic conventional CD4+ 
T cells of Bcl11bF/F/Foxp3­Cre mice had a larger percentage 
of activated CD44hi population compared with WT (Fig. 6 F), 
similar to the Bcl11bF/F/CD4­Cre mice. Furthermore, the 
CD4+ T cells infiltrating the colons of 5–6­mo­old Bcl11bF/F/ 
Foxp3­Cre mice produced higher levels of Th1 and Th17 
cytokines compared with age­matched controls (Fig. 6 H) 
but  less  pronounced  than  in  diseased  Bcl11bF/F/CD4­Cre 
mice. These results demonstrate that conditional removal of 
Bcl11b solely in Treg cells causes IBD with infiltrations of Th1 
and Th17 cytokine–producing CD4+ T cells in the colon, 
similar to Bcl11bF/F/CD4­Cre mice.
Figure 5.  Provision of WT Treg cells prevents IBD development in Bcl11bF/F/CD4-Cre mice. (A) Sorted WT Foxp3-GFP+ Treg cells were transferred 
into 4–5-wk-old Bcl11bF/F/CD4-Cre mice, as described in Materials and methods, and the weight of the mice was assessed weekly. Asterisks indicate sta-
tistical significance between the Treg cell transferred and untransferred groups (*, P < 0.05; determined by unpaired two-tailed Student’s t test). (B) Colon 
gross anatomy of Bcl11bF/F/CD4-Cre (KO), WT Treg cell–transferred Bcl11bF/F/CD4-Cre (WT Tregs → KO), and WT mice. (C) H&E staining of colon sections 
from the mice in B. (D) Alcian blue counterstained with Nuclear Fast red of colon sections from the mice in B. Goblet cells are blue. (C and D) Histological 
images are from similar areas along the length of the colon of the three groups of mice. Bars, 100 µm. (E) Histological scores of colitis, conducted as de-
scribed in Table S1. (P < 0.05, determined by unpaired two-tailed Student’s t test.) Error bars indicate SD. (F) CD4+ and CD8+ T cell frequencies within the 
total lymphocyte population isolated from colon LP and epithelial compartment (IEL). (A–F) Data are representative of two independent experiments with 
three to five mice per group. (G) Intracellular cytokines in gated CD4+ T cells isolated from the colon of the indicated groups of mice. (H) Sorted WT 
CD45.1+/CD45.2+/Foxp3-GFP+ Treg cells were transferred into Bcl11bF/F/CD4-Cre/CD45.2+ mice, and WT (CD45.1+) and Bcl11b-deficient (CD45.1) cells were 
evaluated 6–7 wk after the transfer. Splenocytes were stained for CD4, CD45.1, and Foxp3 and analyzed by flow cytometry. Numbers in boxes indicate the 
frequencies of the donor (CD45.1+) and recipient (CD45.1) cells within the Foxp3+ population. Foxp3 mean fluorescence intensity (MFI) in Bcl11b-deficient 
and WT cells is indicated. (G and H) Data are representative of three independent experiments each with two to three mice per group.JEM Vol. 208, No. 10 
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the intron after the untranslated exon 1 of Foxp3 gene (Zheng 
et al., 2010), whereas CNS­3 is localized in the intron after 
the first coding exon (Zheng et al., 2010). We conducted 
chromatin immunoprecipitations (ChIPs) followed by quan­
titative PCR (qPCR) and found that Bcl11b strongly associ­
ated with the promoter and CNS­1, less efficiently with the 
CNS­2, and did not associate with CNS­3 (Fig. 7 E). We then 
inspected the proximal region of the promoter, shown to be 
bound in the ChIP assays, and found a potential Bcl11b­binding 
site, located at position 89 from the transcription start site 
(TSS; Fig. S7 E). We mutated this site to AAA (Fig. S7 E), 
which is known not to be bound by Bcl11b (Avram et al., 
2002; Cismasiu et al., 2006), in a construct that contains 
the Foxp3 promoter upstream of and the Foxp3 enhancer 1 
(Smad enhancer) downstream of Firefly luciferase (Tone et al., 
2008). The mutation significantly reduced the reporter activity 
in response to activation (Fig. S7 E), suggesting that this site is 
important for Foxp3 promoter activity. In conclusion, these   
results demonstrate that Bcl11b regulates expression of the Foxp3 
gene and associates predominantly with the Foxp3 gene pro­
moter and the CNS­1 and CNS­2 regulatory regions and 
that the potential Bcl11b­binding site in the Foxp3 promoter 
is important for its activation.
might regulate Foxp3 expression as a consequence of altered 
TCR signaling in Bcl11b­deficient Treg cells. We first evaluated 
the CD3 levels and found a very modest reduction in mRNA 
levels (Fig. S6, A and B) and a minor reduction in the surface 
levels, and only in the CD4­Cre system (Fig. S7, A and C). We 
further evaluated the early activation marker CD69, which is 
normally up­regulated in response to TCR  signaling,  and   
the  response  of  Bcl11b­deficient Treg cells was similar to   
WT, both for the CD4­Cre and Foxp3­Cre systems (Fig. S7, 
B and D). These results suggest that Bcl11b­deficient Treg cells 
respond to TCR stimulation similar to WT, and therefore it is 
unlikely that the reduction in the Foxp3 levels is caused by 
altered TCR signaling.
Considering that Bcl11b is a transcription factor, we next 
investigated whether Bcl11b binds to Foxp3 gene regulatory 
regions. The definition of these regions is given based on the 
information provided in Kim and Leonard (2007) and up­
dated after Zheng et al. (2010). We specifically investigated the 
promoter and the conserved noncoding sequences CNS­1, 
CNS­2, and CNS­3, which are known to play a critical role 
in the control of this gene expression (Mantel et al., 2006; 
Kim and Leonard, 2007; Tone et al., 2008; Kitoh et al., 2009; 
Zheng et al., 2010). CNS­1 and CNS­2 are both localized in 
Figure 6.  Bcl11bF/F/Foxp3-Cre mice fail 
to gain weight only after 20 wk of age 
and show colon inflammation with infil-
tration of proinflammatory cytokine–
producing CD4+ T cells. (A) Weight of 
Bcl11bF/F/Foxp3-Cre mice between 2 and 6 mo 
of age. 6–10 mice/group were evaluated. As-
terisks indicate statistical significance deter-
mined by unpaired two-tailed Student’s t test 
(*, P < 0.05). (B) Colon gross anatomy repre-
sentative for 5–6-mo-old Bcl11bF/F/Foxp3-Cre 
mice and age-matched controls. (C) H&E 
staining (top) and Alcian blue counterstained 
with Nuclear Fast red (bottom) of colon sec-
tions of 5–6-mo-old Bcl11bF/F/Foxp3-Cre and 
age-matched controls. Goblet cells are blue. 
Histological images are from similar areas 
along the length of the colon. Bars, 100 µm. 
(B and C) Data are representative of five  
pairs of mice. (D) Colitis histological scale of 
5–6-mo-old Bcl11bF/F/Foxp3-Cre and age-
matched controls, using the criteria in Table S1.   
(A and D) Error bars indicate SD. (E) Frequencies 
of CD4+ and CD8+ T cells in spleen of Bcl11bF/F/
Foxp3-Cre and WT mice. (F) Frequencies of 
CD44+CD4+ T cells in spleen of Bcl11bF/F/
Foxp3-Cre and WT mice. Data are representa-
tive of three pairs of mice. (G) Frequencies of 
CD4+ and CD8+ T cells in the colon LP and 
intraepithelial compartment (IEL) of Bcl11bF/F/
Foxp3-Cre and WT mice. (H) Cytokine produc-
tion by CD4+ T cells isolated from Bcl11bF/F/Foxp3-Cre and WT mice colons. Cells were isolated and activated as described in Materials and methods, fol-
lowed by staining for surface CD4 and intracellularly for the indicated cytokines, and analyzed by flow cytometry. Frequencies of cytokine-producing 
CD4+ T cells are indicated. Data are representative of three pairs of mice.2076 Bcl11b controls regulatory T cells | VanValkenburgh et al.
that Bcl11b associated with the CNS­1, we investigated 
whether the absence of Bcl11b causes alterations in the   
induction of Foxp3 gene expression in conventional CD4+  
T cells in response to Tgf­1 and iTreg cell generation. Our 
results demonstrate that Bcl11b is required for peripheral in­
duction of Foxp3 in the conventional CD4+  T cells in response 
to Tgf­1 (Fig. 7 F), which is in agreement with Bcl11b bind­
ing to the CNS­1 (Fig. 7 E). These results demonstrate that 
Bcl11b plays a critical role in Foxp3 induction in response to 
Tgf­1, potentially through association with CNS­1.
Bcl11b-deficient Treg cells show reduced expression  
of IL-10 gene and elevated levels of proinflammatory  
cytokine genes
To further determine whether other alterations in the Bcl11b­
deficient Treg cells contribute to their affected function, we 
profiled expression of genes in Bcl11b­deficient Treg cells versus 
WT, both in the CD4­Cre and Foxp3­Cre systems (Fig. S6,   
A and B). Importantly, Foxp3 itself was found down­regulated, 
and together with it, several Treg signature genes, some depen­
dent and some independent of Foxp3 (Fig. S6, A and B). 
However, CD25, Gitr, CTLA4, Icos, and CD103 were not 
found altered at the expression level (not depicted), and their 
surface levels were either equal or elevated in Treg cells from 
Bcl11bF/F/CD4­Cre mice and Foxp3­Cre mice (Fig. S8,  
A and B), suggesting that it is unlikely that Bcl11b­deficient 
Treg cells have poor suppressor activity related to these mark­
ers. Interestingly, there was a major reduction in the IL­10 
mRNA levels (Fig. 8 A and Fig. S6). IL­10 is known to play 
an important role in Treg suppressive function, particularly in 
colitis (Miyara and Sakaguchi, 2007; Vignali et al., 2008; Wing 
and Sakaguchi, 2010). Mice deficient in IL­10 develop spon­
taneous  inflammation  of  the  large  intestine  (Kühn  et  al., 
1993). Removal of the IL-10 gene only in CD4+ T cells also 
results  in  inflammation  of  the  colon  (Roers  et  al.,  2004), 
whereas conditional removal only in Treg cells causes IBD, 
though less severe (Rubtsov et al., 2008). Not only the mRNA 
levels of IL­10 were down­regulated in Bcl11b­deficient   
Treg cells, but importantly, the protein levels were also reduced 
(Fig. 8 B and Fig. S6 C). In addition, several effector CD4+ 
T cell genes, including IL­17 and IFN­, as well as IL­22 were 
found up­regulated (Fig. S6). Additionally the intracellular 
levels of the proinflammatory cytokines IL­17 and IFN­ 
and TNF were found elevated as well (Fig. 8 B). Interestingly, 
Bcl11b­deficient Treg cells showed a modest up­regulation of 
several NK marker mRNAs (Fig. S6), including NK1.1; how­
ever, this was not reflected in an increased Nk1.1+ population 
in Treg  cells  from  Bcl11bF/F/CD4­Cre  mice  or  Bcl11bF/F/
Foxp3­Cre mice (Fig. S8, C and D). These results demonstrate 
that  Bcl11b­deficient Treg  cells  showed  reduced  levels  of   
IL­10, which is important in suppressor function, and also ele­
vated levels of several effector cytokines, suggesting that Bcl11b 
contributes to the repression of proinflammatory cytokine gene 
expression in Treg cells, either directly or indirectly, and overall 
demonstrate that Bcl11b is a critical transcriptional regulator 
of Treg cell genetic program.
Bcl11b plays a critical role in the induction of Foxp3 gene 
during generation of induced Treg cells (iTreg cells) from 
conventional CD4+ T cells
It has been recently demonstrated that CNS­1 is indispens­
able for peripheral induction of the Foxp3 gene and genera­
tion of iTreg cells from conventional CD4+ T cells but not for 
thymic Treg cell differentiation (Zheng et al., 2010). Considering 
Figure 7.  Altered expression of Foxp3 in Bcl11b-deficient Treg cells 
of Bcl11bF/F/CD4-Cre and Bcl11bF/F/Foxp3-Cre mice and altered 
induction of Foxp3 during generation of iTreg cells. (A and C) Evalua-
tion of Foxp3 protein levels in Treg cells from Bcl11bF/F/CD4-Cre (A) and 
Bcl11bF/F/Foxp3-Cre (C) versus control mice. Splenocytes were surface 
stained for CD4, fixed and permeabilized, and further stained with anti-
Foxp3 antibodies. Numbers indicate the percentages of CD4+Foxp3+ cells 
among all splenocytes, and the ratio between KO and WT Foxp3 mean 
fluorescence intensity (MFI) is indicated below. The results are representa-
tive for four pairs of mice. (B and D) Relative Foxp3 mRNA levels in sorted 
GFP+ Bcl11b-deficient Treg cells from Bcl11bF/F/CD4-Cre/Foxp3-GFP (B) and 
Bcl11bF/F/Foxp3-Cre (D) mice versus control levels evaluated by qRT-PCR. 
The data show one representative experiment of two with cells sorted 
from two to three mice, or multiple mice in the case of Bcl11bF/F/CD4-Cre/
Foxp3-GFP mice. Bcl11bF/F/Foxp3-Cre mice and their controls were 5–6 mo 
of age. (E) ChIP assays with anti-Bcl11b or IgG antibodies. The immuno-
precipitated DNA was amplified with primers corresponding to the  
indicated regulatory regions. Binding was normalized to the input, as 
described in Material and methods. Enrichment by Bcl11b is indicated as 
fold increase versus IgG. Data are derived from a representative experi-
ment of two. (F) Foxp3-GFPCD4+CD45rbhi cells from Bcl11bF/F/CD4-Cre/
Foxp3-GFP+ and Foxp3-GFP+ WT mice were sorted and incubated in com-
plete media in the presence of cross-linked anti-CD3e, 100 U IL-2, and  
10 ng Tgf-, for 3 d, and then stained for CD4 and Foxp3 and analyzed by 
FACS. Data are representative of three independent experiments.JEM Vol. 208, No. 10 
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a CD4+CD8+ T cell population in the IEL compartment, 
which produced elevated levels of Tnf. Based on the expres­
sion of Tcr­, these cells seem to be mature and presented a 
slight increase in the frequencies of CD8ab versus CD8aa, 
compared with WT. This population is unlikely to be related 
to the CD4+CD8aa suppressive population, previously identi­
fied in the small intestine IEL compartment (Das et al., 2003), 
and may rather participate in the IBD pathology through the 
production of Tnf. Even though effector CD4+ T cells are 
responsible for the production of proinflammatory cytokines 
that cause tissue damage, Treg cells are responsible for main­
taining peripheral tolerance and keeping these cells in check 
(Vignali et al., 2008). Removal of Bcl11b at the DP stage of   
T cell development caused premature up­regulation of the 
gut­homing markers integrin 47 and CCR9 in both effec­
tor CD4+ T cells and Treg cells, conferring ability to both types 
of cells to accumulate into the gut. Nevertheless, our results 
demonstrate that Bcl11b­deficient Treg cells have reduced sup­
pressor activity, both when the gene is removed starting with 
DP thymocytes or solely in Treg cells. These results suggest that, 
although present in the colon, Bcl11b­deficient Treg cells were 
unable to suppress the reactive CD4+ T cells. Provision of   
WT Treg cells prevented the disease, demonstrating that it is 
mainly the defect in the Treg cells that is responsible for the 
disease in Bcl11bF/F/CD4­Cre mice. Moreover, supporting 
our findings, conditional removal of Bcl11b only in Treg cells 
with the use of the Foxp3­Cre strain also resulted in in­
flamed intestine and failure to gain weight, albeit much later 
in life. The late onset of the disease in Bcl11bF/F/Foxp3­Cre 
mice is caused by the delayed removal of Bcl11b in this model 
because the Foxp3­Cre deleter used in this study is a low Cre­
expressing line. Even if later and milder, the disease of Foxp3­
Cre mice mirrored that of the Bcl11bF/F/CD4­Cre mice.   
In support of the common defective function of Bcl11b­
deficient Treg  cells  of  Bcl11bF/F/CD4­Cre  and  Bcl11bF/F/
Foxp3­Cre mice comes also the fact that their genetic pro­
grams  were  similarly  altered  compared  with WT,  and  the 
Treg cells of both models had affected suppressive function. 
Specifically, expression profiling of Bcl11b­deficient Treg cells 
from  Bcl11bF/F/CD4­Cre  and  Bcl11bF/F/Foxp3­Cre  mice 
showed similar deregulated genes, which provided valuable 
insights on defects in their function that lead to the pathology 
observed in these mice. In both models, Foxp3 protein and 
mRNA levels were reduced, and we found that Bcl11b as­
sociated with the Foxp3 promoter, as well as with CNS­1 and 
CNS­2, but not with CNS­3 (Kim and Leonard, 2007; Zheng   
et al., 2010). Foxp3 promoter was shown to contain NFAT 
and AP1 motifs, in addition a GC box (Kim and Leonard, 
2007). We found that mutation of a potential Bcl11b­binding 
site (Avram et al., 2002; Cismasiu et al., 2006) located at 89 
from the TSS in the Foxp3 promoter attenuated the activity 
of the promoter, suggesting that this site is important. In ad­
dition, we found that in the absence of Bcl11b, there was a 
significant reduction in the generation of iTreg cells from con­
ventional CD4+ T cells in response to Tgf­1. CNS­1 plays an 
important role in the induction of the Foxp3 gene expression   
Bcl11b associates with critical control regions  
of the IL-10 gene
Considering the finding that IL­10 mRNA levels were re­
duced in Bcl11b­deficient Treg cells, we further investigated 
whether Bcl11b associated with the IL-10 gene promoter 
and/or other previously characterized regulatory regions of 
these genes, such as CNS+6.5 and CNS­9 (Jones and Flavell, 
2005). ChIP assays demonstrated that Bcl11b associated with 
the IL-10 promoter and with CNS+6.5, a conserved non­
coding potent regulatory sequence localized 6.5 kb down­
stream of IL-10 TSS (Jones and Flavell, 2005), but not with 
CNS­9, positioned 9 kb upstream of the TSS (Fig. 8 C; Jones 
and Flavell, 2005). These results demonstrate that Bcl11b as­
sociates with regulatory regions in the IL-10 gene localized in 
the promoter, as well as at the 3 end of the gene, likely par­
ticipating in the regulation of this gene expression.
DISCUSSION
Our results demonstrate that the absence of Bcl11b, either 
starting with DP thymocytes or only in Treg cells, results in 
IBD, associated with marked infiltration of proinflammatory 
cytokine–producing CD4+ T cells in the colon. In addition 
to the proinflammatory cytokine–producing CD4+ T cells, 
Bcl11bF/F/CD4­Cre mice showed a noticeable increase of 
Figure 8.  Treg cells from Bcl11bF/F/CD4-Cre mice show reduced IL-10 
expression and up-regulation of proinflammatory cytokines, and 
Bcl11b binds to the IL-10 promoter and noncoding sequence 
CNS+6.5. (A) IL-10 mRNA levels in Treg cells from Bcl11bF/F/CD4-Cre and 
WT mice evaluated by qRT-PCR analysis. (B) Flow cytometry analysis of  
IL-10, IL-17, Tnf, and Ifn- in Treg cells from Bcl11bF/F/CD4-Cre/Foxp3-GFP 
and Foxp3-GFP colon LP. Data are representative of four pairs of mice.  
(C) ChIP assays with anti-Bcl11b or IgG antibodies. The immunoprecipi-
tated DNA was amplified with primers corresponding to the indicated 
regulatory regions. Binding was normalized to the input, as described in 
Materials and methods. Enrichment by Bcl11b is indicated as fold increase 
versus IgG. This is one representative experiment out of two.2078 Bcl11b controls regulatory T cells | VanValkenburgh et al.
Tnf, Ifn­, and IL­17. Decreased Foxp3 levels were previously 
shown to cause immune disease by subverting the suppressor 
function of Treg cells and conferring them characteristics of 
effector cells (Wan and Flavell, 2007). At the moment, we do 
not know whether up­regulation of the proinflammatory cyto­
kine genes is caused by reduced Foxp3 expression or Bcl11b 
is directly implicated in the repression of these genes’ expres­
sion in Treg cells. Other transcription factors such as Eos were 
recently shown to repress effector gene expression in Treg cells 
(Pan et al., 2009). In this regard, the idea that effector CD4+ 
T cells, as well as Treg cells, have the capacity to redirect their 
functional programs because their genomic plasticity has re­
cently emerged (Xu et al., 2007; Zhou et al., 2009).
Another potential mechanism implicated in the reduced 
suppression of Bcl11b­deficient Treg cells may come from 
the fact that Bcl11b­deficient Treg cells had decreased Stat3 
mRNA levels, which may contribute to their reduced ability 
to  suppress Th17  immune  responses,  as  has  been  recently 
shown for Stat3­deficient Treg cells (Chaudhry et al., 2009).
In relation to the reduced levels of Foxp3, Bcl11b­deficient 
Treg cells also had deregulated expression of multiple genes 
known to be Foxp3 dependent (Hill et al., 2007). Though the 
deregulated expression of these genes may be a consequence 
of lower Foxp3 levels, it is also possible that Bcl11b may asso­
ciate with Foxp3 complexes and participate in regulation of 
Foxp3­dependent genes, being one of the transcription fac­
tors that provides help to Foxp3 to maintain the genetic 
program and keeps the identity of Treg cells. Bcl11b­deficient 
Treg cells also had deregulated expression of Treg cell signature 
genes that are not dependent of Foxp3 (Hill et al., 2007), 
raising the possibility that Bcl11b may participate in regula­
tion of expression of Foxp3­independent genes. In addition 
to deregulation in the Treg cell–specific program, Bcl11b­
deficient Treg cells showed up­regulation of several NK and   
Fc receptor mRNAs; however, NK1.1 was not up­regulated 
on the surface of Treg cell and only on the surface of Bcl11b­
deficient CD8+ T cells of Bcl11bF/F/CD4­Cre mice. Our 
results demonstrate that the role of Bcl11b is not only to 
keep the identity of T cells, and not allow expression of genes 
specific to other lineages, but also to keep the identity of spe­
cific subtypes of T cells such as Treg cells, perhaps by working 
in association with T cell subset–specific transcription factors.
MATERIALS AND METHODS
Mice. Bcl11bF/F/CD4­Cre mice have been previously described (Albu et al., 
2007). Foxp3­Cre mice were purchased from The Jackson Laboratory and 
backcrossed on a C57BL/6 background for five generations using the Speed 
Congenics Technology  provided  by The  Jackson  Laboratory.  Foxp3­GFP 
mice were a gift from A. Rudensky (Memorial Sloan­Kettering Cancer Center, 
New  York, NY) and were crossed with Bcl11bF/F/CD4­Cre mice to generate 
Bcl11bF/F/CD4­Cre/Foxp3­GFP mice, and Foxp3­Cre–GFP mice were 
crossed with Bcl11bF/F mice to obtain Bcl11bF/F/Foxp3­Cre mice. Mice 
were maintained under specific pathogen­free conditions in the Animal 
Resource Facility of Albany Medical College. Mice were sacrificed between 
6–14 wk of age, except for the Foxp3­Cre mice, which were sacrificed at 5–6 
mo  of  age,  unless  otherwise  specified. The  experiments  were  conducted   
according to animal protocols approved by the Albany Medical Center Insti­
tutional Animal Care and Use Committee.
and the generation of iTreg cells (Zheng et al., 2010), and our data 
show that Bcl11b bound to CNS­1. Thus, Bcl11b is likely 
to also play an important contribution in the induction of 
Foxp3 expression in peripheral conventional CD4+ T cells 
and generation of iTreg cells in response to Tgf­ through 
CNS­1–mediated control. We also found that Bcl11b bound 
to CNS­2 but not to CNS­3. CNS­2 was demonstrated to 
play a critical role in expression of Foxp3, being induced by 
IL­2 through Stat5 (Zorn et al., 2006), and additionally by 
TCR signaling through CREB (Kim and Leonard, 2007). 
We thus investigated whether reduced expression of Foxp3 
in the absence of Bcl11b is a consequence of altered TCR 
signaling, considering that Bcl11b­deficient T cells have been 
shown to have altered TCR signaling (Albu et al., 2007; Li   
et al., 2010a,b; Zhang et al., 2010). However, our results in­
dicated that the up­regulation of CD69 after TCR activa­
tion was similar to WT, thus suggesting that altered TCR 
signaling is not the cause for reduced Foxp3 expression. The 
Runx1–Cbfb  complex  has  been  recently  demonstrated  to 
be required for optimal expression of Foxp3 by association 
with both Foxp3 promoter and with CNS­2 (Kitoh et al., 
2009; Rudra et al., 2009). One of the two Runx1­binding 
sites in the CNS­2 are in the vicinity of a GC­rich sequence, 
raising the possibility that Bcl11b might associate with the 
Runx1–Cbfb complex and cooperate in Foxp3 expression 
maintenance. Foxp3 itself was recently found to be in a large 
complex with Runx–Cbfb and to bind in a Runx–Cbfb­ 
dependent  manner  to  CNS­2  (Kitoh  et  al.,  2009;  Zheng 
et al., 2010). It is therefore possible that Runx–Cbfb and 
Foxp3 associate in a common complex with Bcl11b to regu­
late Foxp3 expression and Treg cell lineage stability.
Other  transcription  factors  recently  shown  to  regulate 
Foxp3 expression include E2a, found to bind to the Foxp3 
promoter and induce its expression in response to Tgf­. This 
required Id3 for the inhibition of the Gata3­mediated repres­
sive activity on Foxp3 expression (Maruyama et al., 2011).
Our  results  show  that  CD25,  Gitr,  CTLA4,  Icos,  and 
CD103 surface levels were either equal or elevated in Bcl11b­
deficient Treg cells, suggesting that it is unlikely that these cells 
have poor suppressive activity related to these markers. How­
ever, Bcl11b­deficient Treg cells showed reduced levels of 
IL­10, which may also contribute to the reduced suppressive 
function of Bcl11b­deficient Treg cells. Studies have shown 
that IL­10–deficient mice lack Treg cells that are capable to 
control inflammatory responses in the intestine (Kühn et al., 
1993; Roers et al., 2004; Rubtsov et al., 2008). We found that 
Bcl11b binds to critical conserved noncoding regulatory se­
quences in the IL­10 locus, including the promoter, CNS+6.5, 
but not CNS­9. Interestingly, CNS+6.5 was found to contain 
c­Jun and JunB and regulate IL­10 expression in Th2 cells 
(Wang et al., 2005). It remains a question whether Jun pro­
teins might be implicated in the regulation of IL­10 expres­
sion in Treg cells and eventually compete or cooperate with 
Bcl11b in this process.
Furthermore,  Bcl11b­deficient Treg  cells  showed  up­
regulation  of  proinflammatory  gene  expression,  including JEM Vol. 208, No. 10 
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classification were conducted using DAVID (Database for Annotation, 
Visualization, and Integrated Discovery) version 6.7 (Huang et al., 2009).
qRT-PCR. RNA and qRT­PCR was conducted as previously described 
(Cismasiu et al., 2006). The primers for qPCR were chosen such as to extend 
products under 200 bp, with no formation of primer dimmers and cross in­
trons. The relative abundance of each message was normalized to actin and 
calculated as 2(Ct gene  Ct actin), where Ct represents the threshold cycle for 
each transcript.
ChIP. ChIP assays were conducted using sorted Foxp3­GFP Treg cells or 
Dynabead­enriched CD4+CD25+ Treg cells, according to our previously pub­
lished protocol (Cismasiu et al., 2006), with the difference that anti­Bcl11b 
antibodies were preloaded on anti–rabbit IgG­Dynabeads, and the precipi­
tated DNA was analyzed by qPCR. The primers for Foxp3 promoter and 
CNS­1, CNS­2, and CNS­3 regions were previously described (Kim and 
Leonard, 2007; Kitoh et al., 2009; Zheng et al., 2010). The primers for IL­10 
promoter and IL­10 gene regulatory regions CNS­9 and CNS+6.45 were 
also previously described (Ahyi et al., 2009; Lee et al., 2009). The transcrip­
tion factor– or IgG­bound DNA was evaluated based on the following for­
mula: 2ct of the immunoprecipitated sample divided by 2ct of the input, 
where ct is the threshold cycle, followed by corrections for the input dilu­
tion. The IgG values were represented as 1, and the transcription factor–
bound DNA was represented as fold enrichment.
Statistical analysis. Differences between Bcl11bF/F/CD4­Cre, Bcl11bF/F/
Foxp3­Cre, and control mice under all experimental conditions were ana­
lyzed by the two­tailed Student’s t test and expressed as the mean ± SD.   
P ≤ 0.05 was considered significant.
Online supplemental material. Fig. S1 shows FACS analysis of mLNs 
and Peyer’s patch lymphocytes, including CD62L and CD44 in Bcl11bF/F/ 
CD4­Cre mice. Fig. S2 shows FACS analysis of the CD4+CD8+ T cell popu­
lations within the colon epithelial compartment, absolute numbers of CD8+ 
T cell populations within the colon, and FACS analysis of NK1.1 markers   
within the spleens of Bcl11bF/F/CD4­Cre mice, as well as weight experi­
ments of Bcl11bF/F/CD4­Cre/2/ and 2/ mice. Fig. S3 shows immuno­
fluorescence microscopy of the large intestine in Bcl11bF/F/CD4­Cre mice. 
Fig. S4 shows FACS analysis of gut­homing markers in splenocytes and 
in vitro maintenance of WT and Bcl11bF/F/CD4­Cre Treg cells during the   
in vitro suppression assay showed in Fig. 4. Fig. S5 shows spleen gross anatomy 
and gut­homing markers of splenocytes in Bcl11bF/F/Foxp3­Cre mice, as 
well as removal of Bcl11b in splenocytes of Bcl11bF/F/Foxp3­Cre mice at 
5 and 20 wk of age compared with Bcl11bF/F/CD4­Cre mice. Fig. S6 shows 
gene expression profiles of Treg cells for Bcl11bF/F/CD4­Cre and Bcl11bF/F/ 
Foxp3­Cre mice and FACS analysis of IL­10 in Treg cells from Bcl11bF/F/
Foxp3­Cre versus WT mice. Fig. S7 shows FACS analysis of CD3 within   
Treg  cells  from  splenocytes  in WT,  Bcl11bF/F/CD4­Cre,  and  Bcl11bF/F/
Foxp3­Cre mice, as well as the response of Bcl11b­deficient Treg cells from 
WT, Bcl11bF/F/CD4­Cre, and Bcl11bF/F/Foxp3­Cre mice to TCR stimula­
tion. Fig. S8 shows FACS analysis of maturation and activation Treg cell mark­
ers and NK1.1 levels in splenocyte Treg cells of WT, Bcl11bF/F/CD4­Cre, 
and Bcl11bF/F/Foxp3­Cre mice. Table S1 shows colitis histological scores. 
The Supplemental materials and methods provide information in regard to 
antibodies used in the study, immunohistochemistry, in vitro stimulation of   
Treg cells, and luciferase reporter assays. Online supplemental material is avail­
able at http://www.jem.org/cgi/content/full/jem.20102683/DC1.
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